LMAT - LeMaitre Vascular Inc Stock Price, Fair Value and News

62.63USD-0.41 (-0.65%)Market Closed

Market Summary

USD62.63-0.41

Market Closed

-0.65%

LMAT Alerts

1 major insider sales recently.

LMAT Stock Price

View Fullscreen

LMAT RSI Chart

LMAT Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

46.77

Price/Sales (Trailing)

7.28

EV/EBITDA

28.25

Price/Free Cashflow

38.32

LMAT Price/Sales (Trailing)

LMAT Profitability

EBT Margin

20.40%

Return on Equity

10.11%

Return on Assets

8.68%

Free Cashflow Yield

2.61%

LMAT Fundamentals

LMAT Revenue

Revenue (TTM)

193.5M

Rev. Growth (Yr)

19.36%

Rev. Growth (Qtr)

3.1%

LMAT Earnings

Earnings (TTM)

30.1M

Earnings Growth (Yr)

50.44%

Earnings Growth (Qtr)

12.84%

Breaking Down LMAT Revenue

Last 7 days

-6.0%

Last 30 days

-5.4%

Last 90 days

8.7%

Trailing 12 Months

20.7%

How does LMAT drawdown profile look like?

LMAT Financial Health

Current Ratio

6.51

LMAT Investor Care

Dividend Yield

0.89%

Dividend/Share (TTM)

0.56

Shares Dilution (1Y)

1.09%

Diluted EPS (TTM)

1.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	169.2M	177.2M	185.6M	193.5M
2022	158.1M	159.5M	160.2M	161.7M
2021	134.7M	150.5M	152.5M	154.4M
2020	119.3M	114.7M	122.0M	129.4M
2019	108.1M	110.5M	115.5M	117.2M
2018	102.7M	104.0M	103.3M	105.6M
2017	92.1M	95.1M	98.0M	100.9M
2016	79.7M	82.2M	86.3M	87.7M
2015	73.3M	75.0M	76.5M	78.4M
2014	65.9M	68.1M	70.3M	71.1M
2013	58.2M	59.8M	61.4M	64.5M
2012	57.0M	56.3M	55.3M	56.7M
2011	56.8M	57.8M	58.7M	57.7M
2010	0	52.6M	54.3M	56.1M
2009	0	0	0	50.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of LeMaitre Vascular Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 22, 2024	lemaitre george w	acquired	709,693	47.9263	14,808	chairman and ceo
Mar 08, 2024	kamke trent g	sold	-309,684	68.1824	-4,542	senior v. p., operations
Mar 07, 2024	roush john a	sold	-517,500	69.00	-7,500	-
Mar 05, 2024	jasinski lawrence j	sold	-344,925	67.5	-5,110	-
Mar 04, 2024	lemaitre george w	sold	-2,489,740	68.0258	-36,600	chairman and ceo
Mar 01, 2024	lemaitre george w	sold	-2,511,880	67.8539	-37,019	chairman and ceo
Feb 29, 2024	jasinski lawrence j	acquired	-	-	593	-
Feb 29, 2024	pellegrino joseph p jr	acquired	1,225,730	36.1678	33,890	chief financial officer
Feb 29, 2024	pellegrino joseph p jr	acquired	-	-	2,649	chief financial officer
Feb 29, 2024	pellegrino joseph p jr	sold	-	-	-2.00	chief financial officer

Which funds bought or sold LMAT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	18.56	117,246	420,855	0.02%
Apr 16, 2024	Ausbil Investment Management Ltd	reduced	-13.98	85.00	966,424	0.48%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-60.97	-729,947	612,768	0.02%
Apr 15, 2024	Legato Capital Management LLC	unchanged	-	185,357	1,281,280	0.16%
Apr 15, 2024	WEST PACES ADVISORS INC.	unchanged	-	278	1,924	-%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	reduced	-1.99	46,904	368,519	-%
Apr 12, 2024	Bridge City Capital, LLC	added	2.65	810,034	4,857,820	1.77%
Apr 12, 2024	Annex Advisory Services, LLC	added	5.3	325,606	1,735,230	0.06%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	added	3.24	9,424	54,946	0.01%
Apr 11, 2024	CONGRESS ASSET MANAGEMENT CO /MA	added	12.01	10,447,700	44,201,300	0.32%

Are Funds Buying or Selling LMAT?

Are funds buying LMAT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LMAT

No. of Funds

LMAT Alerts

1 major insider sales recently.

Unveiling LeMaitre Vascular Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.96%	1,548,870	SC 13G/A
Feb 12, 2024	lemaitre george w	10.3%	2,283,204	SC 13G/A
Jan 22, 2024	copeland capital management, llc	5.7%	1,259,961	SC 13G
Jan 22, 2024	blackrock inc.	14.8%	3,296,788	SC 13G/A
Jan 05, 2024	conestoga capital advisors, llc	9.26%	2,061,262	SC 13G/A
Feb 09, 2023	vanguard group inc	6.72%	1,477,542	SC 13G/A
Jan 31, 2023	lemaitre george w	11.5%	2,532,694	SC 13G/A
Jan 26, 2023	blackrock inc.	14.9%	3,284,565	SC 13G/A
Jan 20, 2023	blackrock inc.	14.9%	3,284,565	SC 13G
Jan 18, 2023	conestoga capital advisors, llc	8.81%	1,938,886	SC 13G/A

Recent SEC filings of LeMaitre Vascular Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	ARS	ARS
Apr 16, 2024	DEF 14A	DEF 14A
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading

Peers (Alternatives to LeMaitre Vascular Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.1B	-5.83%	1.66%	31.91	4.55	-8.12%	-17.45%
BDX	67.4B	19.5B	-2.32%	-8.43%	53.63	3.46	4.02%	-22.04%
ALGN	22.6B	3.9B	-4.99%	-13.70%	50.88	5.86	3.42%	23.09%
BAX	20.1B	14.8B	-4.86%	-7.71%	7.58	1.36	2.12%	209.17%
MID-CAP
ATR	9.1B	3.5B	-0.64%	16.68%	32.12	2.62	4.97%	18.89%
HSIC	9.0B	12.3B	-5.34%	-15.09%	21.61	0.73	-2.44%	-22.68%
BIO	8.2B	2.7B	-12.68%	-39.24%	-12.88	3.07	-4.68%	82.43%
XRAY	6.3B	4.0B	-7.94%	-25.15%	-46.91	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-1.55%	17.10%	-564.74	9.35	33.86%	89.83%
PDCO	2.3B	6.6B	-3.92%	-2.28%	11.91	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-5.32%	-19.06%	-1.85	0.39	7.73%	-1066.14%
ANIK	381.5M	166.7M	1.82%	-7.51%	-4.61	2.29	6.67%	-456.34%
ANGO	253.5M	324.0M	17.44%	-27.90%	-1.32	0.78	-3.19%	-337.41%
APYX	45.7M	52.3M	-25.42%	-56.00%	-2.44	0.87	17.61%	19.28%
AEMD	3.7M	3.7M	-14.97%	255.00%	-0.3	0.99	5.77%	8.23%

LeMaitre Vascular Inc News

Latest updates

LeMaitre Vascular Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	3.1%	49.00	47.00	50.00	47.00	41.00	39.00	42.00	40.00	40.00	38.00	41.00	36.00	38.00	36.00	25.00	31.00	30.00	29.00	29.00	28.00	28.00
Gross Profit	8.0%	33.00	31.00	32.00	31.00	26.00	25.00	28.00	26.00	26.00	25.00	27.00	24.00	24.00	23.00	17.00	20.00	20.00	20.00	20.00	19.00	19.00
Operating Expenses	6.6%	23.00	22.00	23.00	23.00	19.00	19.00	22.00	18.00	18.00	16.00	16.00	16.00	15.00	13.00	12.00	16.00	15.00	14.00	14.00	15.00	12.00
S&GA Expenses	6.2%	10.00	10.00	10.00	11.00	9.00	8.00	8.00	8.00	7.00	7.00	7.00	6.00	6.00	5.00	5.00	8.00	7.00	7.00	8.00	8.00	7.00
R&D Expenses	3.0%	4.00	4.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00
EBITDA Margin	-	0.25*	-	0.23*	0.22*	0.23*	0.24*	0.26*	0.30*	0.31*	0.32*	0.33*	0.31*	0.29*	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	1.00	1.00	0.00	1.00	1.00	1.00	0.00	-	-	-	-	-	-
Income Taxes	22.5%	3.00	2.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Earnings Before Taxes	15.1%	11.00	10.00	10.00	8.00	8.00	6.00	6.00	8.00	8.00	8.00	10.00	7.00	9.00	9.00	5.00	4.00	5.00	6.00	6.00	5.00	7.00
EBT Margin	5.3%	0.20*	0.19*	0.18*	0.16*	0.17*	0.17*	0.19*	0.22*	0.22*	0.23*	0.24*	0.23*	-	-	-	-	-	-	-	-	-
Net Income	12.8%	8.00	8.00	8.00	6.00	6.00	5.00	4.00	6.00	6.00	7.00	8.00	6.00	7.00	8.00	4.00	3.00	5.00	5.00	5.00	4.00	6.00
Net Income Margin	5.9%	0.16*	0.15*	0.14*	0.12*	0.13*	0.13*	0.14*	0.17*	0.17*	0.18*	0.19*	0.18*	-	-	-	-	-	-	-	-	-
Free Cashflow	-9.1%	11.00	12.00	11.00	2.00	3.00	7.00	9.00	4.00	4.00	13.00	9.00	5.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	3.8%	347	334	326	315	310	302	299	292	293	289	247	247	253	262	256	185	188	170	163	160	153
Current Assets	6.8%	195	182	174	165	162	153	148	141	140	134	90.00	91.00	94.00	102	92.00	90.00	92.00	100	98.00	95.00	94.00
Cash Equivalents	34.4%	24.00	18.00	19.00	17.00	19.00	17.00	21.00	16.00	14.00	17.00	22.00	24.00	27.00	29.00	20.00	11.00	12.00	12.00	13.00	15.00	26.00
Net PPE	1.9%	22.00	21.00	21.00	19.00	18.00	15.00	16.00	17.00	17.00	17.00	16.00	15.00	15.00	14.00	16.00	15.00	15.00	14.00	14.00	14.00	14.00
Goodwill	0%	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	66.00	27.00	40.00	40.00	6.00	3.00	30.00	30.00
Liabilities	7.7%	49.00	45.00	43.00	41.00	42.00	41.00	41.00	35.00	39.00	40.00	61.00	70.00	80.00	101	103	36.00	40.00	28.00	25.00	27.00	23.00
Current Liabilities	2.9%	30.00	29.00	26.00	24.00	25.00	23.00	23.00	18.00	22.00	22.00	21.00	22.00	25.00	44.00	44.00	17.00	21.00	19.00	17.00	19.00	20.00
Shareholder's Equity	3.2%	298	289	284	274	268	261	258	258	254	249	186	178	173	161	153	149	148	142	138	133	130
Retained Earnings	4.9%	115	110	106	101	98.00	95.00	92.00	91.00	88.00	84.00	80.00	74.00	71.00	65.00	60.00	58.00	57.00	54.00	51.00	48.00	46.00
Additional Paid-In Capital	1.3%	201	198	197	192	189	187	185	183	182	179	119	117	115	110	108	107	106	104	101	100	98.00
Shares Outstanding	0.1%	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	21.00	22.00	21.00	21.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,300	-	-	-	879	-	-	-	729	-	-	-	289	-	-	-	262	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-9.1%	10,746	11,823	11,903	2,279	4,077	7,342	9,248	4,711	5,056	14,075	9,897	6,074	14,152	14,112	5,347	1,189	5,594	4,470	4,334	-219	6,571
Share Based Compensation	6.9%	1,404	1,313	1,312	1,290	684	1,186	1,136	1,167	886	797	869	927	753	687	803	779	547	655	694	746	555
Cashflow From Investing	77.0%	-2,261	-9,851	-9,639	-2,964	-402	-8,460	-973	-536	-7,246	-51,368	-1,402	-1,060	3,673	1,347	-57,886	-25.00	-3,546	-5,728	-3,070	-11,756	1,257
Cashflow From Financing	14.0%	-2,686	-3,122	502	-1,825	-2,122	-2,147	-2,585	-2,380	-1,159	33,365	-10,539	-7,965	-21,005	-6,474	61,375	-1,741	-2,220	16.00	-2,842	424	-1,303
Dividend Payments	0.0%	3,116	3,117	3,116	3,099	2,750	2,750	2,745	2,743	2,406	2,401	2,267	2,262	1,936	1,925	1,917	1,917	1,701	1,691	-	-	1,372
Buy Backs	13240.0%	667	5.00	9.00	172	490	3.00	4.00	145	428	286	-	88.00	279	234	-	57.00	237	423	-	-	63.00

LMAT Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net sales	$ 193,484	$ 161,651	$ 154,424
Cost of sales	66,435	56,755	53,042
Gross profit	127,049	104,896	101,382
Sales and marketing	41,054	32,921	27,655
General and administrative	31,832	28,745	25,501
Research and development	16,966	13,294	11,801
Restructuring	485	3,107	0
Total operating expenses	90,337	78,067	64,957
Income from operations	36,712	26,829	36,425
Other income (expense):	3,077	986	197
Interest expense	(0)	(0)	2,219
Other income (loss), net	(314)	(325)	(116)
Income before income taxes	39,475	27,490	34,287
Provision for income taxes	9,370	6,854	7,380
Net income	$ 30,105	$ 20,636	$ 26,907
Earnings per share of common stock: (in dollars per share)	$ 1.36	$ 0.94	$ 1.27
Diluted (in dollars per share)	$ 1.34	$ 0.93	$ 1.25
Weighted-average shares outstanding: (in shares)	22,217	21,975	21,157
Diluted (in shares)	22,423	22,171	21,475
Cash dividends declared per common share (in dollars per share)	$ 0.56	$ 0.5	$ 0.44

LMAT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 24,269	$ 19,134
Short-term marketable securities	80,805	63,557
Accounts receivable, net of allowances of $941 at December 31, 2023 and $835 at December 31, 2022	25,064	22,040
Inventory and other deferred costs	58,080	50,271
Prepaid expenses and other current assets	6,380	6,731
Total current assets	194,598	161,733
Property and equipment, net	21,754	17,901
Right-of-use leased assets	18,027	15,634
Goodwill	65,945	65,945
Other intangibles, net	41,711	46,527
Deferred tax assets	1,003	1,745
Other assets	3,740	991
Total assets	346,778	310,476
Current liabilities:
Accounts payable	3,734	2,903
Accrued expenses	23,650	19,967
Acquisition-related obligations	24	573
Lease liabilities - short-term	2,471	1,886
Total current liabilities	29,879	25,329
Lease liabilities - long-term	16,624	14,710
Deferred tax liabilities	107	69
Other long-term liabilities	2,268	2,167
Total liabilities	48,878	42,275
Stockholders’ equity:
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding	0	0
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 23,655,716 shares at December 31, 2022, and 23,477,784 shares at December 31, 2021	239	237
Additional paid-in capital	200,755	189,268
Retained earnings	115,430	97,773
Accumulated other comprehensive loss	(4,625)	(6,031)
Treasury stock, at cost; 1,568,595 shares at December 31, 2022 and 1,554,905 shares at December 31, 2021	(13,899)	(13,046)
Total stockholders’ equity	297,900	268,201
Total liabilities and stockholders’ equity	$ 346,778	$ 310,476

About LeMaitre Vascular Inc

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

CEO	Mr. George W. LeMaitre
WEBSITE	lemaitre.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	591

LeMaitre Vascular Inc Frequently Asked Questions

What is the ticker symbol for LeMaitre Vascular Inc? What does LMAT stand for in stocks?

LMAT is the stock ticker symbol of LeMaitre Vascular Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LeMaitre Vascular Inc (LMAT)?

As of Wed Apr 17 2024, market cap of LeMaitre Vascular Inc is 1.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LMAT stock?

You can check LMAT's fair value in chart for subscribers.

What is the fair value of LMAT stock?

You can check LMAT's fair value in chart for subscribers. The fair value of LeMaitre Vascular Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of LeMaitre Vascular Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LMAT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is LeMaitre Vascular Inc a good stock to buy?

The fair value guage provides a quick view whether LMAT is over valued or under valued. Whether LeMaitre Vascular Inc is cheap or expensive depends on the assumptions which impact LeMaitre Vascular Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LMAT.

What is LeMaitre Vascular Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, LMAT's PE ratio (Price to Earnings) is 46.77 and Price to Sales (PS) ratio is 7.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LMAT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on LeMaitre Vascular Inc's stock?

In the past 10 years, LeMaitre Vascular Inc has provided 0.242 (multiply by 100 for percentage) rate of return.